In supercentenarians, a rare hybrid “killer-helper” T cell made up nearly a fifth of all T cells — hinting the immune system keeps adapting even in extreme old age.
The revenue-cycle giant is adding an AI platform that files and clears insurer authorizations — targeting one of the most-hated bottlenecks in US healthcare.
Columbia engineers linked lab-grown human bone and lung tissue on a chip and watched circulating breast-cancer cells choose their targets — and soften them up in advance.
The manufacturer will produce an AAV9 gene therapy for GM2 gangliosidosis — a group of fatal inherited disorders — developed with Queen’s University ahead of planned clinical trials.
Analyzing antibody “fingerprints” across thousands of people, a deep-learning model spotted markers that flag who is likely to mount a weak vaccine response in advance.
Vitestro’s Aletta autonomously finds a vein and draws blood in adults, with one trained phlebotomist supervising up to three machines — a possible answer to a worsening staffing shortage.
Ultragenyx’s Genglycos delivers a working gene to the liver in glycogen storage disease type Ia, aiming to free patients from the relentless routine of round-the-clock cornstarch dosing.
The antibody cut new abnormal bone formation by up to 90% in a trial for fibrodysplasia ossificans progressiva — a devastating disorder in which soft tissue slowly turns to bone.
The Dutch biotech will push its brain-signaling drug through a mid-stage trial for cognitive impairment in schizophrenia — a common, disabling problem with no approved treatment.
Researchers used AI to redesign antibody fragments so they can work inside cells — a long-standing hurdle — and aimed them at the toxic proteins behind Alzheimer’s, Parkinson’s and motor neurone disease.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.
PIKTOR, an oral combination that hits the PI3K/AKT/mTOR pathway, won fast-track status alongside chemotherapy for endometrial cancer that has progressed despite prior treatment.